Sugi Predict

Sugi Predict / Compounds / SCHEMBL3470595

SCHEMBL3470595

SCHEMBL3470595

CC(C)(O)C=Cc1cc(F)cc2c(-c3ccnc(NC4CC(C)(C)NC(C)(C)C4)n3)c[nH]c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 8/20 0.38
▸ MAPK8 P45983 3/20 0.38
▸ MAPK9 P45984 3/20 0.38
▸ MAPK10 P53779 1/20 0.38
▸ CDC7 O00311 4/20 0.37
▸ MAP4K4 O95819 4/20 0.37
▸ CDK1 P06493 4/20 0.37
▸ PIM1 P11309 4/20 0.37
▸ PRKACA P17612 4/20 0.37
▸ GSK3B P49841 4/20 0.37
▸ HIPK2 Q9H2X6 4/20 0.37
▸ MKNK2 Q9HBH9 4/20 0.37
▸ IRAK4 Q9NWZ3 4/20 0.37
▸ JAK2 O60674 3/20 0.37
▸ FLT3 P36888 3/20 0.37
▸ JAK3 P52333 3/20 0.37
▸ PIM3 Q86V86 3/20 0.37
▸ AKT3 Q9Y243 3/20 0.37
▸ CCNB1 P14635 3/20 0.37
▸ CCNB2 O95067 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470590 1.00 RET (0.38) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL13638322 0.89 RET (0.35) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL4479867 0.85 MAPK8 (0.42) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL3478545 0.85 MAPK8 (0.42) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL3477322 0.84 AR (0.44) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL4481970 0.83 AR (0.47) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL3477789 0.82 CDK2 (0.41) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL3476930 0.82 AR (0.46) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL3476506 0.77 MAP3K14 (0.54) RETMAPK8MAPK9MAPK10CDC7
SCHEMBL13638598 0.76 MAPK8 (0.39) RETMAPK8MAPK9MAPK10CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615898-B1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2014-10-29 — — EP claimed
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 — — US claimed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 — — US claimed
WO-2010134939-A2 MAMMALIAN GENES INVOLVED IN INFECTION Zirus, Inc. (US) 2010-11-25 — — WO disclosed
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 — — US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK RET 3044/4885MAPK8 197/4885MAPK9 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.